# US 2019/0315854 A1 · Antibodies, composition and kits comprising same, and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315854 A1
- Document ID: US20190315854A1
- Status: Published application
- Kind: A1
- Application number: 16/200,512
- Filed: 2018-11-26
- Published: 2019-10-17
- Earliest claimed: 2016-05-27
- Assignees: Beijing Vdjbio Co., Ltd.
- Applicants: Beijing VDJBio Co., Ltd.
- Inventors: Ziqiang Li
- Web page: https://patentgrep.com/patent/US20190315854A1

## CPC

- C07K 16/248: {IL-6}
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/06: Antiasthmatics
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/567: Framework region [FR]
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Provided are novel antibodies with high target affinities against an IL6 receptor. Further provided are compositions containing such antibodies and methods of using the same.

## Claims

### Claim 1

An anti-Interleukin-6 receptor (IL-6R) antibody, wherein the antibody:
(a) comprises a heavy chain and a light chain, wherein the heavy chain comprises an amino acid sequence with about or greater than 85% sequence identity to a sequence selected from SEQ ID NO. 2, wherein the light chain comprises an amino acid sequence with about or greater than 85%, sequence identify to SEQ ID NO. 4;
(b) exhibits a binding affinity (KD) for human IL-6 receptor (IL-6R) of 1 nM or less as determined by surface plasmon resonance at 37° C., wherein the IL-6R has as an amino acid sequence shown in SEQ ID No. 91; and
(c) the heavy chain does not comprise a sequence shown in SEQ ID NO. 3 and SEQ ID NO. 1.

### Claim at position 2

2-9. (canceled)

### Claim 10 (depends on 1)

The antibody of claim 1, wherein the antibody:
exhibits a binding affinity (KD) for IL-6 receptor (IL-6R) that is greater than the affinity of an antibody comprising a heavy chain of an amino acid sequence of SEQ ID NO. 1 and a light chain of an amino acid sequence of SEQ ID NO. 2.

### Claim at position 4

11-18. (canceled)

### Claim 19 (depends on 1)

The antibody of claim 1, wherein the antibody exhibits a binding affinity (KD) for IL-6 receptor (IL-6R) of 0.001 nM or less as determined by surface plasmon resonance at 37° C.

### Claim at position 6

20-21. (canceled)

### Claim 22 (depends on 1)

The antibody of claim 1, wherein:
(a) the antibody exhibits a binding affinity (KD) for IL-6 receptor (IL-6R) that is greater than an affinity of an antibody comprising a heavy chain of an amino acid sequence of SEQ ID NO. 3 and a light chain of an amino acid sequence of SEQ ID NO. 4; and
(b) the antibody inhibits proliferation of DS-1 cells by at least 40% after 72 hours at a concentration of 0.032 μg/mL or less in an MTS cell-proliferation assay.

### Claim at position 8

23-33. (canceled)

### Claim 34 (depends on 1)

The antibody of claim 1, wherein:
(a) the heavy chain comprises one or more mutations at positions 51, 57, 58, 99, 103, 106, and 116 with respect to SEQ ID NO. 1; and/or
(b) the light chain comprises one or more mutations at positions 89 and 93 with respect to SEQ ID NO. 2.

### Claim 35 (depends on 34)

The antibody of claim 34, wherein the heavy chain comprises two, three, four, five or more mutations at positions 51, 57, 58, 99, 103, 106, and 116 with respect to SEQ ID NO. 1.

### Claim at position 11

36-38. (canceled)

### Claim 39 (depends on 34)

The antibody of claim 34, wherein the mutation at position 51 of the heavy chain is selected from the group consisting of from Y to F, from Y to R, from Y to W and from Y to K.

### Claim 40 (depends on 34)

The antibody of claim 34, wherein the mutation at position 57 of the heavy chain is from I to M.

### Claim at position 14

41-42. (canceled)

### Claim 43 (depends on 34)

The antibody of claim 34, wherein the mutation at position 103 of the heavy chain is selected from the group consisting of from T to I, from T to A, from T to G, from T to L, from T to M, from T to Y, and from T to R.

### Claim at position 16

44-45. (canceled)

### Claim 46 (depends on 34)

The antibody of claim 34, wherein the light chain comprises one or more mutations at positions 89 and 93 with respect to SEQ ID NO: 2.

### Claim at position 18

47-53. (canceled)

### Claim 54 (depends on 1)

The antibody of claim 1, wherein the antibody has a pH dependence of binding affinity for IL-6R higher than 5, 10, 15, or 20, and wherein the pH dependence is defined as the ratio between the binding affinity for the IL-6R at pH7.4 and at pH6.0.

### Claim at position 20

55-60. (canceled)

### Claim 61 (depends on 1)

The antibody of claim 1, wherein the antibody has mutations selected from:
(a) Y51F, I57M, T58I, S99C, and T103I in the heavy chain with respect to SEQ ID NO. 1;
(b) Y51F, I57M, S99T, and T103I in the heavy chain with respect to SEQ ID NO. 1;
(c) Y51F, I57M, S99N, and T103I in the heavy chain with respect to SEQ ID NO. 1;
(d) Y51F, I57M, S99C, T103I, and T116I in the heavy chain with respect to SEQ ID NO. 1;
(e) Y51F, I57M, S99C, and T103I in the heavy chain; and Q89G and T93R in the light chain with respect to SEQ ID NO. 1; and
(f) Y51F, I57M, and T103I in the heavy chain; and Q89G and T93R in the light chain with respect to SEQ ID NO: 2.

### Claim at position 22

62-70. (canceled)

### Claim 71 (depends on 1)

A method of treating a disease or condition comprising administering the antibody of claim 1 to a subject in need thereof.

### Claim 72 (depends on 71)

The method of claim 71, wherein the disease or condition comprises infection, endotoxic shock associated with infection, arthritis, rheumatoid arthritis, psoriatic arthritis, systemic onset juvenile idiopathic arthritis (JIA), inflammatory bowel disease (IBD), systemic lupus erythematosus (SLE), asthma, pelvic inflammatory disease, Alzheimer's Disease, Crohn's disease, ulcerative colitis, irritable bowel syndrome, multiple sclerosis, ankylosing spondylitis, dermatomyositis, uveitis, Peyronie's Disease, coeliac disease, gallbladder disease, Pilonidal disease, peritonitis, psoriasis, vasculitis, surgical adhesions, stroke, Type I Diabetes, lyme arthritis, meningoencephalitis, immune mediated inflammatory disorders of the central and peripheral nervous system, autoimmune disorders, pancreatitis, trauma from surgery, graft-versus-host disease, transplant rejection, heart disease, bone resorption, burns patients, myocardial infarction, Paget's disease, osteoporosis, sepsis, liver/lung fibrosis, periodontitis, hypochlorhydia, solid tumors (renal cell carcinoma), liver cancer, multiple myeloma, prostatic cancer, bladder cancer, pancreatic cancer, neurological cancers, and B-cell malignancies (e.g., Casteleman's disease, certain lymphomas, chronic lymphocytic leukemia, and multiple myeloma).

### Claim 73 (depends on 1)

A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable excipient.

### Claim 74 (depends on 1)

A kit comprising the antibody of claim 1 in a container.

### Claim at position 27

75-76. (canceled)

### Claim 77 (depends on 1)

An isolated polynucleotide encoding the antibody of claim 1.

### Claim 78 (depends on 77)

A vector comprising the isolated polynucleotide of claim 77.

### Claim 79 (depends on 78)

A cell comprising the vector of claim 78.

### Claim at position 31

80-82. (canceled)
